drugset / Trial / NCT03019419
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis
Timeline
- Start
- 2017-04-24
- Primary completion
- 2020-12-23
- Completion
- 2020-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perampanel | Small molecule | 4 mg | — |
| Subject | Perampanel | Small molecule | 8 mg | — |